Efficacy of MK0557 in Combination With Sibutramine or Orlistat
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obesity
Intervention: MK0557 (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to
obese subjects to compare the effect on body weight over a six month period.
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men and women between the ages of 18-65 who are considered obese (have a body mass
index between 30 and 43)
Exclusion Criteria:
- Subject has high blood pressure or is taking any high blood pressure medicine
- History of psychiatric disorder, stroke, or heart disease
Locations and Contacts
Additional Information
Starting date: December 2003
Ending date: December 2003
Last updated: September 19, 2007
|
